HALO Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals, Inc. has a net margin of 49.46% compared to Halozyme Therapeutics, Inc.'s net margin of -2301.55%. Halozyme Therapeutics, Inc.'s return on equity of 139.43% beat Armata Pharmaceuticals, Inc.'s return on equity of --.

Halozyme Therapeutics, Inc. has a consensus price target of $76.00, signalling upside risk potential of 1.19%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 34.73%. Given that Armata Pharmaceuticals, Inc. has higher upside potential than Halozyme Therapeutics, Inc., analysts believe Armata Pharmaceuticals, Inc. is more attractive than Halozyme Therapeutics, Inc..

Halozyme Therapeutics, Inc. has a beta of 0.942, which suggesting that the stock is 5.77% less volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.292, suggesting its more volatile than the S&P 500 by 29.177%.

Halozyme Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Halozyme Therapeutics, Inc. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Halozyme Therapeutics, Inc. quarterly revenues are $354.3M, which are larger than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Halozyme Therapeutics, Inc.'s net income of $175.2M is higher than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Halozyme Therapeutics, Inc.'s price-to-earnings ratio is 15.79x while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics, Inc. is 7.59x versus 55.41x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 49.46% compared to Halozyme Therapeutics, Inc.'s net margin of 21.47%. Halozyme Therapeutics, Inc.'s return on equity of 139.43% beat Johnson & Johnson's return on equity of 33.27%.

Halozyme Therapeutics, Inc. has a consensus price target of $76.00, signalling upside risk potential of 1.19%. On the other hand Johnson & Johnson has an analysts' consensus of $211.38 which suggests that it could grow by 1.87%. Given that Johnson & Johnson has higher upside potential than Halozyme Therapeutics, Inc., analysts believe Johnson & Johnson is more attractive than Halozyme Therapeutics, Inc..

Halozyme Therapeutics, Inc. has a beta of 0.942, which suggesting that the stock is 5.77% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.341, suggesting its less volatile than the S&P 500 by 65.861%.

Halozyme Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.48% to investors and pays a quarterly dividend of $1.30 per share. Halozyme Therapeutics, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Halozyme Therapeutics, Inc. quarterly revenues are $354.3M, which are smaller than Johnson & Johnson quarterly revenues of $24B. Halozyme Therapeutics, Inc.'s net income of $175.2M is lower than Johnson & Johnson's net income of $5.2B. Notably, Halozyme Therapeutics, Inc.'s price-to-earnings ratio is 15.79x while Johnson & Johnson's PE ratio is 20.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics, Inc. is 7.59x versus 5.46x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 49.46% compared to Halozyme Therapeutics, Inc.'s net margin of 33.68%. Halozyme Therapeutics, Inc.'s return on equity of 139.43% beat Merck & Co., Inc.'s return on equity of 39.63%.

Halozyme Therapeutics, Inc. has a consensus price target of $76.00, signalling upside risk potential of 1.19%. On the other hand Merck & Co., Inc. has an analysts' consensus of $110.62 which suggests that it could grow by 1.86%. Given that Merck & Co., Inc. has higher upside potential than Halozyme Therapeutics, Inc., analysts believe Merck & Co., Inc. is more attractive than Halozyme Therapeutics, Inc..

Halozyme Therapeutics, Inc. has a beta of 0.942, which suggesting that the stock is 5.77% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.859%.

Halozyme Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.02% to investors and pays a quarterly dividend of $0.85 per share. Halozyme Therapeutics, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Halozyme Therapeutics, Inc. quarterly revenues are $354.3M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Halozyme Therapeutics, Inc.'s net income of $175.2M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Halozyme Therapeutics, Inc.'s price-to-earnings ratio is 15.79x while Merck & Co., Inc.'s PE ratio is 14.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics, Inc. is 7.59x versus 4.28x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of 49.46% compared to Halozyme Therapeutics, Inc.'s net margin of 13.19%. Halozyme Therapeutics, Inc.'s return on equity of 139.43% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Halozyme Therapeutics, Inc. has a consensus price target of $76.00, signalling upside risk potential of 1.19%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 517.98%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Halozyme Therapeutics, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Halozyme Therapeutics, Inc..

Halozyme Therapeutics, Inc. has a beta of 0.942, which suggesting that the stock is 5.77% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.251, suggesting its less volatile than the S&P 500 by 125.1%.

Halozyme Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Halozyme Therapeutics, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Halozyme Therapeutics, Inc. quarterly revenues are $354.3M, which are larger than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Halozyme Therapeutics, Inc.'s net income of $175.2M is higher than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Halozyme Therapeutics, Inc.'s price-to-earnings ratio is 15.79x while Protalix Biotherapeutics, Inc.'s PE ratio is 25.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics, Inc. is 7.59x versus 2.26x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.